Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials. J of Skin [Internet]. 2022 Mar. 4 [cited 2025 Jul. 22];6(2):s4. Available from: https://skin.dermsquared.com/skin/article/view/1520